Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day
GIAFFER, M. H. ; HOLDSWORTH, C. D. ; LENNARD-JONES, J. E. ; RODRIGUES, C. A. ; MCINTYRE, P. B. ; MANJUNATHA, S. ; BARON, J. H. ; BARRISON, I. G. ; POLSON, R. J. ; HOARE, A. M. ; DAVIES, G. S. R. ; THORNTON, P. C.
Oxford, UK : Blackwell Publishing Ltd
Published 1992
Oxford, UK : Blackwell Publishing Ltd
Published 1992
| ISSN: |
1365-2036
|
|---|---|
| Source: |
Blackwell Publishing Journal Backfiles 1879-2005
|
| Topics: |
Medicine
|
| Notes: |
The efficacy of two doses of balsalazide for the maintenance of remission in patients with ulcerative colitis was compared in a double-blind multicentre trial. Sixty-five patients received a 2 g daily dose, and 68 a 4 g dose. The patient groups were similar at entry for sex, age, and disease distribution. Clinical assessment was carried out at 3-monthly intervals, with sigmoidoscopy, rectal biopsy, and blood tests on entry and at 26 and 52 weeks. Clinical relapse over twelve months was significantly less common on the 4 g dose (36%), than on the 2 g dose (55%), P 〈 0.01. There were eight withdrawals on 2 g daily and 13 on 4 g daily, six and nine respectively being mainly due to gastrointestinal intolerance. It is concluded that balsalazide is a well-tolerated drug, and is effective for the maintenance of remission in patients with ulcerative colitis, the optimal dose being greater than 2 g daily.
|
| Type of Medium: |
Electronic Resource
|
| URL: |